
Autolus Therapeutics Spon Ads Ea Rep 1 Ord Shs (AUTL) Stock
Small cap biotech developing engineered cancer treatments. Here's the price, business snapshot, and what's worth knowing about Autolus Therapeutics Spon Ads Ea Rep 1 Ord Shs in November 2026.
Autolus Therapeutics plc (AUTL) is a clinical‑stage biotechnology company developing engineered T‑cell (CAR‑T) therapies for cancer. With a market capitalisation of roughly $433.8m, it is a small‑cap, research‑intensive group whose value depends heavily on trial results, regulatory decisions and potential partnerships. Investors should know that Autolus has no broad commercial revenue stream today and that clinical milestones and safety data are binary events that can drive significant share‑price moves. The company’s outlook hinges on successful patient outcomes, cost controls and access to funding; this makes the stock suitable primarily for investors comfortable with high volatility, long time horizons and the possibility of capital loss. This summary is for educational purposes only and not personalised advice — consider diversification and professional guidance when assessing suitability.
Autolus Therapeutics Spon Ads Ea Rep 1 Ord Shs (AUTL) Stock Forecast
Analyst price target, next 12 months
$9.15
+688.5% vs today's $1.16
Price range over the last 12 months
Close to its 12-month low
Analysts covering Autolus Therapeutics Spon Ads Ea Rep 1 Ord Shs have a consensus 12-month target of $9.15, above the current price of $1.16.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 19 Nov 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Autolus stock, with a target price of $9.15, indicating strong growth potential.
Financial Health
Autolus Therapeutics is generating moderate revenue and profits, with a decent gross margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical catalysts ahead
Major trial readouts and regulatory decisions can change valuation quickly, offering potential upside but bringing binary risk.
Targeted cancer focus
Programmes aim at specific haematological cancers and possibly solid tumours; scientific progress matters more than short‑term market moves.
Cutting‑edge engineering
Autolus uses advanced T‑cell engineering techniques, which could deliver breakthroughs, though development is costly and uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.